期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

重组人促甲状腺激素在甲状腺疾病诊治中的应用 被引量：6

Utility of recombinant human thyrotropin in the management of thyroid diseases
原文传递
导出
摘要 重组人TSH（rhTSH）于1998年在国外进入临床应用，其临床适应证由辅助DTC患者的随访检查和检测逐渐扩展到辅助131I清除手术后残留甲状腺组织。近期研究表明，rhTSH在辅助131I治疗DTC转移灶、辅助131I治疗非毒性结节性甲状腺肿、提高18F-FDGPET对甲状腺癌的诊断效能及对先天性甲状腺功能减退症的病因鉴别诊断等多方面亦有应用潜力。 Recombinant human TSH （rhTSH） was introduced into clinical practice in 1998. The initial clinical application of rhTSH in facilitating follow-up studies for patients with DTC has been extended into aiding 131I ablation for post-surgical thyroid remnant. Recent studies have revealed the potential of rhTSH in enhancing 131I uptake for metastatic DTC foci and non-toxic multi-nodular goiter （MNG） as well as in strengthening 18F-FDG PET scans for characterizing DTC lesions and helping differential diagnosis of con- genital hypothyroidism.
作者 关海霞 陆汉魁
机构地区 中国医科大学附属第一医院内分泌科、内分泌研究所、辽宁省内分泌疾病重点实验室 上海交通大学附属第六人民医院核医学科
出处 《中华核医学与分子影像杂志》 CSCD 北大核心 2012年第4期311-314,共4页 Chinese Journal of Nuclear Medicine and Molecular Imaging
基金 国家自然科学基金（30801120）
关键词 促甲状腺激素 重组 甲状腺疾病 发展趋势 Thyrotropin Recombinant Thyroid diseases Trends
分类号 R817.4 [医药卫生—影像医学与核医学] R581 [医药卫生—内分泌]
  • 相关文献

参考文献27

  • 1Szkudlinski MW, Thotakura NR, Bucci I, et al. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology, 1993, 133 : 1490-1503.
  • 2Lawrence JE, Emerson CH, Sullaway SL, et al. The effect of recombinant human tsh on the thyroid ^123I uptake in iodide treated normal subjects. J Clin Endocrinol Metab, 2001, 86: 437-440.
  • 3Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma ( phase Ⅰ/Ⅱ study). J Clin Endocrinol Metab, 1994, 78 : 188-196.
  • 4Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 2001, 86: 1447-1463.
  • 5Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med, 1997, 337: 888-896.
  • 6Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab, 1999, 84: 3877-3885.
  • 7Gramza A, Schuff KG. Recombinant human thyroid stimulating hormone in 2008 : focus on thyroid cancer management. Onco Targets Ther, 2009, 1 : 87-101.
  • 8Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab, 2003, 88: 3668-3673.
  • 9Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol, 2006, 154: 787- 803.
  • 10American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19 : 1167-1214.

二级参考文献10

  • 1NCCN Clinical Practice Guidelines in Oncology (Thyroid Carcinoma). 2010.
  • 2Chung JK, Park Y J, Kim TY, et al. Chnical significance of elevated level of serum antthyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Ciin Endocrinol, 2002, 57: 215-221.
  • 3Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Taskforce. Thyroid, 2006, 16:109-142.
  • 4Pelizzo MR, Merante Boschin I, Toniato A, et ai. Dianosis, treatment, prognostic factors, and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol, 2008,33:359-379.
  • 5Mazzaferri E. NCCN thyroid carcinoma practice guidelines. Oneology, 1999, 13:391-442.
  • 6Schlumberger M, Ricard M, Pacini F. Clinical use of recombinant human TSH in thyroid cancer patients. Eur J Endocrinol, 2000, 143 : 557 -563.
  • 7American Association of Clinical Endocrinologists. American College of Endocrinology 2001 AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract, 2001,7:202-220.
  • 8Richard J, Robbins R, Michael Tuttle, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawl are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab, 2001,86:619-625.
  • 9Vaiano A, Claudio Traino A, Boni G, et al. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stinmlation versus hypothyroidism induced by L-thyroxine withdrawal. Nucl Med Cmnmun, 2007,28:215-223.
  • 10Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med, 1992, 33 : 1132-1136.

共引文献5

同被引文献80

  • 1ZHURui-sen YUYong-li LUHan-kui LUOQuan-yong CHENLi-bo.Clinical study of 312 cases with matastatic differentiated thyroid cancer treated with large doses of ^(131)I[J].Chinese Medical Journal,2005(5):425-428. 被引量：10
  • 2I Molinaro E, Viola D, Passannanti P, et al. Recombinant human TSH(rhTSH) in 2009: new perspectives in diagnosis and therapy [J]. Q J Nucl Med Mol Imaging, 2009, 53(5 ) : 490-502.
  • 3Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi nI : a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone with- drawal[J]. J Clin Endocrinol Metab, 2002, 87 (9) : 4063-4068.
  • 4Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine abla- tion of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an inter- national, randomized, controlled study[J]. J Clin Endocrinol Metab, 2006, 91(3): 926-932.
  • 5Schlumberger M, Ricard M, De Pouvourville G, et al. How the availability of recombinant human TSH has changed the manage- ment of patients who have thyroid cancer[J]. Nat Clin Pract En- docrinol Metab, 2007, 3(9): 641-650.
  • 6Hinscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation af- ter rhTSH or hormone withdrawal[J]. J Nucl Med, 2006, 47(4) : 648-654.
  • 7Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-as- sisted radioactive iodine remnant ablation achieves short-term clin- ical recurrence rates similar to those of traditional thyroid hormone withdrawal[J]. J Nucl Med, 2008, 49(5 ) : 764-770.
  • 8Zanotti-Fregonara P, Hindi6 E, Toubert ME, et al. What role for re- combinant human TSH in the treatment of metastatic thyroid can- cer?[J]. Eur J Nucl Med Mol Imaging, 2009, 36(6): 883-885.
  • 9Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine abla- tion and treatment of differentiated thyroid carcinoma: a compre- hensive review[J]. Endocr Relat Cancer, 2005, 12( 1 ) : 49-64.
  • 10Rosdrio PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 3I is associated with lowered radiotoxicity[J]. J Nucl Med, 2008, 49( 11 ) : 1776-1782.

引证文献6

二级引证文献1931

中华核医学与分子影像杂志
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部